世界の鼻腔内薬物送達市場及び開発パイプライン

◆英語タイトル:Global Intranasal Drug Delivery Market & Pipeline Insight
◆商品コード:KUIK409142
◆発行会社(調査会社):Kuick Research
◆発行日:2014年9月
◆ページ数:566
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD2,400 ⇒換算¥256,800見積依頼/購入/質問フォーム
Multi UserUSD4,800 ⇒換算¥513,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuick Research社の日本における正規販売代理店です。Kuick Research社の概要及び新刊レポートはこちらでご確認いただけます。



【レポートの概要】

Intranasal drug delivery has evolved in the recent years as a significant method of delivering drugs through the nasal route. This method has been identified to have all the potential to achieve significant milestones in the pharmaceutical industry, as it is largely driven by its capability to cure local infections and chronic allergies. The human nose, which has a unique vascular structure, makes it specifically accessible for delivering small molecule drugs and biologics. By taking advantage of the conducive healthcare trends and changing demography, the intranasal drug delivery route is likely to capture the popularity of other leading methods of drug delivery such as oral and parenteral.
The use of nasal sprays and inhalers has had a great impact in improving the drug administration experience, enhancing compliance rates, and ensuring safety. These systems have emerged as a segment with huge potential for the future and are playing an increasingly prominent role in a range of competitive intranasal devices markets. The growth and competitiveness of the intranasal drugs and devices market has led to the extensive development and innovation of new and nth-generation devices which have the capacity to overcome the limitations of the previous drug delivery technologies.

With an increasing number of patients preferring to use self-administering devices like sprays and inhalers to avoid the pain, the market for these products is likely to grow at a substantial rate in the near future. This increasing demand is also having a great impact in terms of attracting new companies into the market. The future years are expected to witness a steady increase in chronic diseases, if not a rapid increase and this is also a major driver of intranasal drug delivery technologies.
The intranasal drug delivery market is likely to witness more developments in formulation techniques, like improvised micro-encapsulation techniques, more use of muco adhesive and surfactant agents and nanotechnology. This would in turn lead to an increased number of new chemical entities which could possibly be considered as the active ingredients for future intranasal drug products. Similarly, it is also expected that modern approaches to vaccination would be increasingly used which could also generate a wide range of new prophylactic and therapeutic products which would be appropriate for delivery through the nasal route.

“Global Intranasal Drug Delivery Market & Pipeline Insight” Report Highlights:
• Intranasal Drug Delivery Market Overview
• Mechanism & Application Intranasal Drug Delivery
• Nasal Drug Delivery System: Powder, Gels, Liquid & Pressurized MDI
• Intranasal Drug Clinical Pipeline Insight by Indication, Phase, Company & Country
• Intranasal Drug Clinical Pipeline: 177 Drugs
• Majority Drugs in Preclinical Phase: 65
• Market Intranasal Drugs: 34

【レポートの目次】

1. Introduction to Intranasal Drug Delivery

2. Intranasal Drug Delivery Mechanism
2.1 Mechanism of Nasal Absorption
2.2 Types of Nasal Drug Delivery System Dosages
2.2.1 Liquid Nasal Formulations
2.2.2 Pressurized MDI
2.2.3 Powder Devices
2.2.4 Nasal Gels

3. Need for Intranasal Drug Delivery

4. Applications of Intranasal Drug Delivery
4.1 Delivery of Non Peptide Pharmaceuticals
4.2 Delivery of Peptide Based Pharmaceuticals
4.3 Delivery of Drugs to Brain through Nasal Cavity
4.4 Delivery of Vaccines through Nasal Route
4.5 Delivery of Diagnostic Drugs

5. Intranasal Drug Delivery Market Overview
5.1 Current Market Scenario
5.2 Intranasal Drug Clinical Pipeline Overview

6. Intranasal Drug Delivery Market Dynamics
6.1 Favorable Market Parameters
6.2 Challenges in Drug Delivery

7. Intranasal Drug Delivery Market Future Outlook
7.1 Future Scenario
7.2 Advances in Delivery Devices

8. Intranasal Drug Clinical Pipeline by Indication, Phase, Company & Country
8.1 Research
8.2 Preclinical
8.3 Clinical
8.4 Phase-I
8.5 Phase-I/II
8.6 Phase-II
8.7 Phase-II/III
8.8 Phase-III
8.9 Preregistration
8.10 Registered

9. Marketed Intranasal Drugs by Indication, Company & Country

10. Suspended & Discontinued Intranasal Drugs in Clinical Pipeline by Indication, Phase, Company & Country
10.1 No Development Reported
10.2 Discontinued
10.3 Market Withdrawal
10.4 Suspended

11. Competitive Landscape
11.1 Aegis Therapeutics
11.2 Archimedes Pharma
11.3 GlaxoSmithKline
11.4 MEDA AB
11.5 MedImmune
11.6 Merck
11.7 NanoBio Corporation
11.8 Novartis
11.9 OptiNose
11.10 Pherin Pharmaceuticals

Figure 1-1: Intranasal Drug Delivery Formulations
Figure 2-1: Intranasal Drug Delivery Mechanism
Figure 2-2: Nasal Drug Delivery System Dosages Forms
Figure 5-1: Composition of Drug Delivery Market
Figure 5-2: Global Intranasal Drug Delivery Market (US$ Billion), 2013-2018
Figure 5-3: Intranasal Drug Delivery Therapeutic Applications
Figure 5-4: Regional Break-up of Intranasal Drug Delivery Market
Figure 5-5: Intranasal Drug Clinical Pipeline by Phase (%), 2014
Figure 5-6: Intranasal Drug Clinical Pipeline by Phase (Number), 2014
Figure 5-7: No Development Reported in Intranasal Drug by Phase (%), 2014
Figure 5-8: No Development Reported in Intranasal Drug by Phase (Number), 2014
Figure 5-9: Discontinued Intranasal Drug in Pipeline by Phase (%), 2014
Figure 5-10: Discontinued Intranasal Drug in Pipeline by Phase (Number), 2014
Figure 5-11: Suspended Intranasal Drug in Pipeline by Phase (%), 2014
Figure 5-12: Suspended Intranasal Drug in Pipeline by Phase (Number), 2014
Figure 11-1: NanoBio Clinical Pipeline
Figure 11-2: Pherin Pharmaceuticals



【掲載企業】

Aegis Therapeutics, Archimedes Pharma, GlaxoSmithKline, MEDA AB, MedImmune, Merck, NanoBio Corporation, Novartis, OptiNose, Pherin Pharmaceuticals


【レポートのキーワード】

鼻腔、薬物送達、ドラッグデリバリーシステム、鼻薬物送達、開発、治験、パイプライン

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[世界の鼻腔内薬物送達市場及び開発パイプライン]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年07月29日現在 197,496 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆